重组人脑利钠肽-沙库巴曲缬沙坦序贯治疗急性心力衰竭的效果分析  

Effect Analysis of Recombinant Human Brain Natriuretic Peptide-Shakubatroxobin in Sequential Treatment of Acute Heart Failure

作　　者：曲玉娟 QU Yujuan(Liaoning Wafangdian Second Hospital Co.,Ltd.Dalian 116300,China)

机构地区：[1]辽宁省瓦房店第二医院有限公司,辽宁大连116300

出　　处：《中国医药指南》2021年第31期102-103,106,共3页Guide of China Medicine

摘　　要：目的针对急性心力衰竭患者实施重组人脑利钠肽-沙库巴曲缬沙坦序贯治疗,进一步对比临床疗效和相关指标变化,探讨治疗有效性和安全性。方法将本院收治确诊为急性心力衰竭患者作为本次研究对象来源,其中随机抽取92例,诊疗时间范围在2020年1月至2020年12月,以随机法设计方式分组。对照组(n=46)患者采用常规治疗措施,观察组(n=46)为重组人脑利钠肽-沙库巴曲缬沙坦序贯治疗,对比治疗疗效的差异。结果从治疗上看,观察组患者NT-proBNP水平优于对照组(P<0.05);在心功能指标上两组差异不大,无统计学意义(P>0.05)。在心力衰竭生存质量量表的评估上,观察组分别为(44.65±13.65)分,对照组则为(52.05±14.73)分,对比具有统计学意义(P<0.05)。与此同时,在低血压的发生率上,观察组为19.56%(9/46),低于对照组的30.43%(14/46),差异具有统计学意义(P<0.05)。最后,观察组患者心力衰竭再入院率为23.91%(11/46),明显低于对照组的47.83%(22/46),对比具有统计学意义(P<0.05)。结论采用重组人脑利钠肽-沙库巴曲缬沙坦序贯治疗急性心力衰竭,有助于改善患者的心功能,同时有效提升了患者的生活质量,可以防止不良事件的发生,具有临床推广价值。Objective In the experiment,patients with acute heart failure will be treated with recombinant human brain natriuretic peptide-Shakubatroxartan sequentially,and the clinical efficacy and changes of related indexes will be further compared to explore effectiveness and safety of treatment.Methods The patients diagnosed with acute heart failure in our hospital were taken as the source of this study,and 92 cases were randomly selected.The diagnosis and treatment time ranged from January 2020 to December 2020,and they were divided into groups by random design.46 cases patients in the control group were treated with routine treatment measures,while those in the observation group(46 cases)were treated with recombinant human brain natriuretic peptideshakubatroxobin sequentially.Compared the difference in the rapeutic effect.Results In terms of treatment,the level of NT-proBNP in the observation group was better than that in the control group,(P<0.05);there was little difference between the two groups in the index of cardiac function,and there was no statistical significance(P>0.05).In addition,in the evaluation of the quality of life scale of heart failure,the scores of the observation group and the control group were(44.65±13.65)and(52.05±14.73)respectively,with statistical significance(P<0.05).Meanwhile,the incidence of hypotension in the observation group was(19.56%,9/46),which was lower than that in the control group(30.43%,14/46),and the difference was statistically significant(P<0.05).Finally,the readmission rate of patients with heart failure in the observation group was 23.91%(11/46),while that in the control group was 47.83%(22/46),with statistical significance(P<0.05).Conclusion The sequential treatment of acute heart failure with recombinant human brain natriuretic peptide-Shakubatroxobin is helpful to improve patients'heart function and improve patients'quality of life effectively,which can prevent the occurrence of adverse events and has clinical promotion value.

关 键 词：心力衰竭 重组人脑利钠肽 沙库巴曲缬沙坦 序贯治疗 急性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]